Compare · GLUE vs SGEN
GLUE vs SGEN
Side-by-side comparison of Monte Rosa Therapeutics Inc. (GLUE) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GLUE and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 19.9x GLUE ($1.18B).
- GLUE has hit the wire 5 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 11 for GLUE).
- Company
- Monte Rosa Therapeutics Inc.
- Seagen Inc.
- Price
- $14.60+6.34%
- $228.86-0.01%
- Market cap
- $1.18B
- $23.34B
- 1M return
- -35.27%
- -
- 1Y return
- +217.74%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2001
- News (4w)
- 5
- 0
- Recent ratings
- 11
- 25
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest GLUE
- Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.
- Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
- President & CEO Warmuth Markus sold $220,219 worth of shares (9,500 units at $23.18), decreasing direct ownership by 2% to 585,038 units (SEC Form 4)
- Chief Operating Officer Champoux Jennifer exercised 4,351 shares at a strike of $3.98 and sold $101,730 worth of shares (4,351 units at $23.38) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- Chief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $139,849 worth of shares (6,000 units at $23.31) as part of a pre-agreed trading plan (SEC Form 4)
- Director Behbahani Ali disposed of 1,015,000 shares and acquired 15,000 shares (SEC Form 4)
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)